חוב כולל להון Fulgent Genetics (FLGT)

The debt-to-equity ratio of Fulgent Genetics, Inc. (FLGT) demonstrates the company's financial stability, with the indicator standing at 0.01. The business is implementing robotic sequencing and AI to accelerate diagnostics. Demand for oncology tests ensures stable growth regardless of economic conditions. Massive cash reserves eliminate liquidity gaps, allowing the company to independently finance the development of new laboratory products.

The ratio determines the degree of financial leverage by comparing total liabilities to net shareholders' equity. By analyzing the debt-to-equity trend, an investor assesses the stability of the capital structure and bankruptcy risks. The metric is calculated as the ratio of total debt to equity, revealing the proportion of borrowed funds used for financing. The low leverage of Fulgent Genetics, Inc. (FLGT) confirms its financial autonomy. This complements the diversification strategy for laboratory services, reducing the overall operational risks of the business.